Boyd Technologies to produce medical masks at Lee facility for COVID fight
LEE — Boyd Technologies, which manufactures products for the medical device and life science industries, is readying its production facility on Route 102 to produce personal protective equipment like medical masks to assist health care agencies battling the COVID-19 pandemic.
While the company doesn't currently produce this kind of equipment, it has a number of production lines that are well-suited to making these materials, Boyd President and CEO Stephen Boyd said in a statement.
"In order to do so, there are some significant technical and raw materials challenges which we are actively working on," said Boyd, who also chairs the Berkshire Innovation Center's board of directors.
Like many of its partners in the health care industry, he said, Boyd Technologies is offering its services in response to calls of support from state and federal agencies as well as its own commercial partners.
"Our mission is to advance health together, and ultimately our goal is to improve the lives of the patients we serve," he said. "We take great pride in our capabilities as a medical device company and feel a profound sense of duty to respond to this call to action. We are working non-stop to do so."
Boyd Technologies, founded in 1979, is an advanced materials and technology company whose service platform provides material sourcing, product development, and advanced manufacturing services to partners in the medical and life sciences fields.
Boyd said the company is committed to using its services to help stem the pandemic.
"We — as a nation — have historically risen to meet challenges and to innovate in circumstances where there is no playbook," Boyd said. "Boyd Technologies is working to be part of the solution to the challenges presented by COVID-19. We are committed to addressing shortages of personal protective equipment for our first responders and healthcare workers on the front lines of this pandemic."
Boyd is the second company from Lee that is responding to the challenges presented by the COVID-19 virus. Berkshire Sterile Manufacturing, a pharmaceutical drug-testing company that also is located on Route 102, is helping to develop a medication that is intended to help reduce inflammation in the lungs of those who already have contracted the virus. Due to a confidentiality agreement, company President and CEO Shawn Kinney has declined to identity the firm with whom his company is working.
On Friday, the company received the medication's raw material, known as active pharmaceutical ingredient, or API, from Memphis, Tenn., where it cleared customs after having been shipped from Switzerland, Kinney said. Berkshire Sterile's role in the process is to make sure this material is viable for sterilized injectable quality.
"Tomorrow, we have a volunteer group of employees coming in on their day off to fill it into vials." Kinney said via email. "We will then test the product to verify that it meets all of its quality requirements before it gets shipped off to the clinic."
Tony Dobrowolski can be reached at firstname.lastname@example.org or 413-496-6224.
TALK TO US
If you'd like to leave a comment (or a tip or a question) about this story with the editors, please email us. We also welcome letters to the editor for publication; you can do that by filling out our letters form and submitting it to the newsroom.